Related Experiment Videos
[Autologous transfusion and hemoglobin SC disease]
B Lecam1, G Woimant, C Gautreau
1Département d'anesthésie-réanimation chirurgicale, établissement de transfusion sanguine de l'AP-HP, Paris, France.
Annales Francaises D'Anesthesie Et De Reanimation
|April 20, 1999
Summary
Autologous blood transfusions in patients with undiagnosed hemoglobin SC disease may be safe for surgery. However, stored red blood cells showed increased hemolysis over time, suggesting careful consideration for transfusion in sickle cell disease patients.
Area of Science:
- Hematology
- Transfusion Medicine
- Genetics
Background:
- Sickle cell disease (SCD) is a group of inherited red blood cell disorders.
- Hemoglobin SC (HbSC) disease is a variant of SCD.
- Autologous blood transfusion (ABT) involves using a patient's own blood.
Observation:
- A patient with undiagnosed HbSC disease received three units of autologous packed red blood cells during orthopedic surgery.
- The transfused blood units were stored for 10 to 31 days at 4°C.
- No adverse clinical reactions were observed during the perioperative period.
Findings:
- Six months later, during an exchange transfusion, stored autologous blood from the same patient showed moderate hemolysis after 12 days and significant hemolysis after 32 days.
- This suggests that red blood cell viability decreases with prolonged storage, even in autologous units.
Implications:
- ABT might be a viable option for managing hemorrhagic surgery in selected patients with sickle cell disease.
- Further research is needed to establish optimal storage conditions and transfusion protocols for ABT in SCD patients.
- Case reports like this contribute to understanding the safety and efficacy of ABT in specific hematological conditions.